X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic's technology platform to the development and manufacturing of its mono- and polyclonal antibody drug candidates.
Lead Product(s): Recombinant Polyclonal Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: GigaGen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 01, 2022
Details:
Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic’s technology platform for the development and manufacturing of GigaGen’s recombinant antibody drugs including GIGA-2050.
Lead Product(s): GIGA-2050
Therapeutic Area: Infections and Infectious Diseases Product Name: GIGA-2050
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: GigaGen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 30, 2021
Details:
Under the agreement, Immunomedics gains commercial rights for application of ProteoNic’s technology platform to the development of specified proprietary products from mammalian cells.
Lead Product(s): Recombinant protein
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immunomedics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
